Complete UK Pricing Guide: What Each Treatment Actually Costs
Mounjaro vs Wegovy vs Ozempic: UK Availability and Licensing
When comparing Mounjaro vs Wegovy vs Ozempic for monthly costs in the UK, it's crucial to understand that only Wegovy holds an MHRA licence for weight management. Wegovy (semaglutide) is specifically approved for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Ozempic, despite containing the same active ingredient as Wegovy, is licensed exclusively for type 2 diabetes treatment, making its promotion for weight management illegal in the UK.
Mounjaro (tirzepatide) represents a dual GIP and GLP-1 receptor agonist, recently approved for weight management with different pricing structures across UK providers. However, Wegovy remains the most established option with comprehensive clinical evidence from the STEP trial programme. The monthly cost comparison between Mounjaro vs Wegovy vs Ozempic becomes meaningful only when considering legally available options for weight management purposes.
Wegovy Monthly Cost Breakdown: Starter to Maintenance
Understanding Wegovy's monthly costs requires following the mandatory dose escalation schedule over 16 weeks. New customers using code FIRST40 pay £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), then £99.99 for 1mg (weeks 9-12), and £139.99 for 1.7mg (weeks 13-16). The maintenance dose of 2.4mg costs £209.99 monthly for ongoing treatment, representing the long-term monthly investment.
Returning customers benefit from the DOSE25 discount code, maintaining these competitive prices throughout their treatment journey. Annual maintenance costs total approximately £2,520 at the 2.4mg dose, making budgeting straightforward. EverydayMeds' bundle options, such as the Ultimate Stability Trio providing three months of 2.4mg maintenance for £649.99, offer convenience and treatment continuity without requiring monthly reorders.
Clinical Evidence: Wegovy's Proven Efficacy in STEP Trials
In clinical trials, patients taking Wegovy alongside diet and exercise achieved significant weight management outcomes. The STEP 1 trial demonstrated approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed around clinically studied weight loss in patients with type 2 diabetes, while STEP 3 achieved approximately 16% with intensive behavioural therapy.
The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, adding significant clinical value beyond weight management. These results support Wegovy's positioning as a prescription-only medicine requiring clinical assessment and ongoing prescriber supervision throughout treatment.
How Wegovy Works: GLP-1 Receptor Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural hormone GLP-1 that regulates appetite and food intake. The medication works on brain appetite centres, potentially reducing food cravings and promoting feelings of fullness after smaller meals. This mechanism supports sustainable weight management when combined with dietary modifications and increased physical activity. Unlike quick fixes, Wegovy addresses the biological factors that influence appetite and satiety. The once-weekly injection via FlexTouch pen provides consistent medication levels, supporting adherence to the treatment regimen. Clinical assessment ensures Wegovy is appropriate for individual circumstances and medical history.
EverydayMeds Ordering Process: Assessment to Delivery
Accessing Wegovy through EverydayMeds begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Our qualified prescribers review each application within standard 3 working days, with express 24-hour review available for urgent cases. Once approved, Wegovy ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. GPhC registration #9012878 ensures pharmaceutical standards and regulatory compliance throughout the supply chain. The streamlined process eliminates traditional pharmacy visits while maintaining clinical oversight and patient safety protocols.
Storage and Practical Considerations for Long-term Treatment
Wegovy requires refrigeration at 2-8°C before first use but offers superior storage flexibility compared to alternatives, remaining stable at room temperature below 30°C for up to 6 weeks once removed from the fridge. This storage advantage provides significant practical benefits for travel, work, or lifestyle flexibility compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design enables easy self-administration with pre-loaded doses, eliminating mixing or preparation requirements. The mandatory dose escalation protocol prevents gastrointestinal side effects while optimising therapeutic benefits. Regular prescriber check-ins ensure treatment remains appropriate and effective throughout the weight management journey.
Budgeting Strategies for Long-term Wegovy Treatment
Planning monthly costs for Wegovy treatment involves understanding both the escalation phase expenses and ongoing maintenance requirements. The initial four-month escalation period totals £414.96 with FIRST40, providing a clear budgeting framework for treatment initiation. Maintenance phase costs of £209.99 monthly remain consistent, enabling accurate annual budgeting of approximately £2,520 for ongoing 2.4mg treatment.
EverydayMeds' bundle options support different budgeting preferences, from Getting Started bundles covering dose transitions to Stay Steady bundles providing multiple months of the same dose. The DOSE25 discount for returning customers ensures consistent pricing throughout treatment duration. Consider maintenance costs as a long-term health investment, particularly given Wegovy's cardiovascular benefits demonstrated in the SELECT trial.
Why Wegovy Leads the UK Weight Management Market
EverydayMeds' transparent Wegovy pricing eliminates hidden costs or subscription surprises common with other providers. Our clinical team, operating under GPhC registration #9012878, ensures every prescription meets MHRA guidelines for this prescription-only medicine. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to help determine which treatment aligns with your medical needs and budget considerations. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, using code FIRST40 for new customers or DOSE25 for returning patients. Transform your approach to weight management with evidence-based treatment backed by comprehensive pharmaceutical support and competitive UK pricing.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
